Text Size: a  |   a 

Mavenclad Improves Relapsing MS Patients' Quality of Life

August 23, 2017

Merck’s Mavenclad (cladribine) tablets significantly improve quality of life among relapsing multiple sclerosis (MS) patients while reducing the number of relapses, according to new analyses of previously unpublished data from clinical trialsassessing the drug.

This new data, published in the Multiple Sclerosis Journal, come just as the European Commission ponders whether to approve the once- rejected therapy to treat relapsing forms of MS. Its decision is expected later this month, seven years after a perceived increased of cancer risk led the European Medicines Agency (EMA) to block Mavenclad.

In 2011, the U.S. Food and Drug Administration (FDA) rejected the medication, forcing its eventual withdrawal from the Australian and Russian markets, where it had already been licensed.

For the study “Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis,” researchers at Queen Mary University of London (QMUL) used data obtained from the EMA through a Freedom of Information request.
They analyzed data from the Phase 3 CLARITY trial (NCT00213135), which compared Mavenclad to placebo. The trial’s 1,326 participants completed a quality-of-life questionnaire that focused on disease aspects such as mobility, self-care, usual activities, pain or discomfort, and anxiety.

After two years, those on Mavenclad had significantly improved their quality of life compared to the control group, particularly in terms of self-care. Mavenclad also helped mobility, which might be related to its ability to prevent relapses and delay progression, researchers said.

READ MORE via MS NEWS TODAY